Saisheng Pharmaceutical: Beijing Saisheng Pharmaceutical Co., Ltd. 2025 annual performance forecast
Securities code: 300485 Securities abbreviation: Saisheng Pharmaceutical Announcement number: 2026-005Beijing Saisheng Pharmaceutical Co., Ltd.
2025 Annual Results Forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Performance forecast for this period
Performance forecast period: January 1, 2025 to December 31, 2025.
Performance forecast situation: Net profit is expected to be positive and it is a situation of turning losses into profits.
Unit: 10,000 yuan
Items This reporting period Net profit attributable to shareholders of listed companies in the same period last year 1,377.37 ~ 2,000 -6,885.31
-2,868.64 ~ -2,347.07
Net profit after deducting non-recurring gains and losses was 1,176, a decrease of 299.58% to 343.93% compared with the same period last year.
2. Communication with the accounting firm
The data related to this performance forecast are the results of preliminary calculations by the company's financial department and have not been audited by an accounting firm. The company has pre-communicated with the annual audit accounting firm on matters related to the performance forecast, and there is no disagreement between the company and the accounting firm regarding the performance forecast for this reporting period.
3. Explanation of reasons for performance changes
The company expects that the net profit attributable to shareholders of listed companies in 2025 will increase compared with the same period last year. The main reason is that during the reporting period, the company's gains and losses from changes in fair value of financial assets and investment income from associates increased compared with the previous period. The financial assets invested by the company mainly include biomedicine, medical equipment and other companies related to the company's main business, as well as professional medical and health investment funds. During the reporting period, gains from changes in fair value and investment income from associates were approximately 19 million yuan, an increase of approximately 110%.
The company expects that the net profit after deducting non-recurring gains and losses in 2025 will decrease compared with the previous period. This is mainly due to the increase in R&D investment during the reporting period compared with the previous period and the provision for impairment of other non-current assets-investment funds.
During the reporting period, the amount of non-recurring gains and losses that are expected to affect the company's net profit is approximately 43 million yuan, mainly due to income from changes in fair value and investment income from trading financial assets.
4. Other related instructions
This performance forecast is the result of preliminary calculations by the company's financial department and has not been audited by an audit agency. The specific financial data will be disclosed in detail in the company's 2025 annual report.
Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd.
January 30, 2026